Table 3.
Treatment-related adverse events occurring in > 5% of patients
| All patients (n = 146) | ||
|---|---|---|
| Any grade | Grade 3–5 | |
| All treatment-related adverse events* | 128 (87.7) | 31 (21.2) |
| RCCEP | 111 (76.0) | 4 (2.7) |
| Hypothyroidism | 23 (15.8) | 0 |
| Aspartate aminotransferase increased | 22 (15.1) | 0 |
| Proteinuria | 18 (12.3) | 0 |
| Alanine aminotransferase increased | 17 (11.6) | 0 |
| Decreased appetite | 12 (8.2) | 1 (0.7) |
| Amylase increased | 11 (7.5) | 3 (2.1) |
| Pruritus | 11 (7.5) | 0 |
| Cough | 10 (6.8) | 0 |
| Pyrexia | 10 (6.8) | 0 |
| Asthenia | 10 (6.8) | 0 |
| Anemia | 10 (6.8) | 2 (1.4) |
| Pneumonitis | 9 (6.2) | 3 (2.1) |
| Hyperthyroidism | 9 (6.2) | 0 |
| Lipase increased | 8 (5.5) | 3 (2.1) |
| Hepatic function abnormal | 8 (5.5) | 0 |
Data are presented in n (%). RCCEP, Reactive cutaneous capillary endothelial proliferation. *The treatment-related adverse event refers to the correlation of the event with treatment was “definitely related”, “possibly related”, or “unassessable”